Rommelag Marks 50 Years of BFS Technology - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Rommelag Marks 50 Years of BFS Technology



Rommelag announced its 50th year of supplying blow-fill-seal machinery, with the brand name bottelpack. Rommelag is a member of the Hansen Group headed by CEO Bernd Hansen, with sales companies in Switzerland, Germany, the US, and China.

All bottelpack machines operate using the blow-fill-seal principle (BFS), a single automatic process in which containers are created from thermoplastic granules (blow), contents are inserted (fill) and closed (seal). BFS technology does not require the cleaning and sterilization processes that are used in other kinds of container production, according to Rommelag. Used for the aseptic packaging of sterile liquids, creams, ointments and vaccines, the machines are equipped with additional modules for QA and monitoring. Modules include aseptic systems for automatic cleaning and sterilization of lines that come into contact with products.

Rommelag reports that aseptic packaging by means of bottelpack BFS systems is gaining popularity and plastic materials offer advantages to manufacturers and users of infusion containers and ampoules. The packaging can be made very thin without risk of breaking, is easily collapsible, and is chemically inert.

Source: Rommelag

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy

Click here